Abstract: Embodiments relate to microparticles containing moxidectin, and a preparation method thereof. Unlike conventional heartworm prevention drugs that have a short half-life and thus require daily or monthly administration, moxidectin is continuously released for at least three months and thus the effect of preventing heartworms can be maintained for at least three months when the microparticles containing moxidectin are administered. In addition, microparticles which have a constant average diameter and a narrow diameter distribution are prepared so that initial over-release of moxidectin is prevented when the microparticles are administered, the release of the drug can be controlled to keep constant the concentration of moxidectin that is valid for at least three months, and foreign body sensation and pain can be reduced when the microparticles are applied in the form of an injection.

Abstract: An aging system for aging a plurality of cells includes a plurality of chambers comprising multiple levels, each of the levels housing a cell; and a crane unit provided adjacent to the chamber, for transporting and delivering cells to each level of the chamber; and the crane unit includes: an upper frame; a lower frame; a pair of masts connecting the upper and lower frames; and a lifting unit coupled to the pair of masts so as to be lifted up and down by being guided by the pair of masts. The crane unit further includes at least one air conditioning fan that blows wind to circulate air so that the temperature distribution of each cell housed in the chamber is uniform.

Abstract: Embodiments relate to microparticles containing moxidectin and a method for preparing same. Unlike conventional drugs for preventing heartworm disease, which have a short half-life and require daily or monthly administration, when the microparticles containing moxidectin are administered, moxidectin is continuously released for 3 months or longer, and thus, a heartworm disease preventive effect can be maintained. In addition, by preparing microparticles having a constant average particle diameter and a narrow diameter distribution width, even when the microparticles are administered, the initial over-release of moxidectin is prevented, and the release of the drug is controlled so that a concentration of moxidectin effective for three months or longer can be kept constant, and when the microparticles are applied as an injection, foreign body sensation and pain can be reduced.

Abstract: An embodiment relates to a novel long-acting injectable composition for preventing or treating androgenetic alopecia containing finasteride. The injectable composition is capable of inhibiting type II 5?-reductase for one month or more with a single injection, thereby limiting the conversion of testosterone to DHT and inhibiting androgen-mediated hair follicle miniaturization. In addition, the injectable composition may increase the mean elimination half-life (t1/2el) of finasteride after in vivo injection, thereby increasing the stability of finasteride, and exhibiting a more predictable and uniform therapeutic effect compared to oral dosage forms.

Abstract: The present disclosure provides a capacitor module including: a capacitor; a first housing having a hexahedron shape and having an inner space in which the capacitor is disposed, the first housing including a pair of cooling parts recessed inwards from a pair of parallel surfaces among outer side surfaces thereof such that a refrigerant flows, a pair of cooling channels disposed inside opposite side surfaces perpendicular to the surfaces of the pair of cooling parts such that the pair of cooling parts communicate with each other, and a through-hole configured to connect each of the cooling channels to the outside such that the refrigerant is introduced or discharged therethrough; and a cooling plate coupled to the first housing so as to seal the cooling parts.

Abstract: The present invention relates to a composition comprising a SETMAR inhibitor for preventing or treating cancer. It has been identified that if SETMAR is inhibited in cancer cells, carcinogenesis reversion, which is the differentiation of cancer cells into normal cells, is successfully achieved, and thus, unlike conventional anticancer agents that simply induce cancer cell death, the present invention can be effectively used as a treatment method excluding the side effect of normal cell death that can occur during anticancer treatment, and converting cancer cells into normal cells.

Abstract: The present disclosure provides a capacitor module including: a capacitor; a first housing having a hexahedron shape and having an inner space in which the capacitor is disposed, the first housing including a pair of cooling parts recessed inwards from a pair of parallel surfaces among outer side surfaces thereof such that a refrigerant flows, a pair of cooling channels disposed inside opposite side surfaces perpendicular to the surfaces of the pair of cooling parts such that the pair of cooling parts communicate with each other, and a through-hole configured to connect each of the cooling channels to the outside such that the refrigerant is introduced or discharged therethrough; and a cooling plate coupled to the first housing so as to seal the cooling parts.

Abstract: Provided is a photosensitive material and a photodetector including the same. According to the present invention, the photodetector may include a photoactive layer having a photocurrent density of at most about 10?6 A/cm2 under a first incidence condition, and having a photocurrent density of at least about 10?4 A/cm2 under a second incidence condition. The wavelength of light under the second incidence condition is the same as the wavelength of light under the first incidence condition, and the intensity of light under the second incidence condition may be greater than the intensity of light under the first incidence condition.

Abstract: According to sustained-release microparticles containing deslorelin, and a preparation method therefor, of the present invention, sustained-release microparticles containing deslorelin in a formulation for subcutaneous administration are provided so that pain can be relieved during administration to animals, and a chemical castration effect can last for 2 to 36 months. In addition, the present invention is effective as a chemical castration agent for 2 to 8 months so as to have an excellent of removing boar taint.

Abstract: A lipid nanoparticles manufacturing chip includes a first raw material supply flow path, a second raw material supply flow path, and a mixer portion connected to the first raw material supply flow path and the second raw material supply flow path and configured for mixing a first raw material supplied through the first raw material supply flow path and a second raw material supplied through the second raw material supply flow path. The mixer portion includes a first stabilizing unit, and a first mixing unit connected to the first stabilizing unit and configured for mixing the first raw material and the second raw material with each other. Mixing of the first raw material and the second raw material is performed more in the first mixing unit than in the first stabilizing unit.

Abstract: A composition for sustained-release injection comprising deslorelin, can prevent initial over-release by adjusting the release rate of deslorelin at a target site and can exhibit the effect of deslorelin for 1 month or more by being exposed in an amount enough to show the effect of deslorelin. Further, the microparticles can prepare microparticles that have a uniform particle size and are capable of exhibiting the effect of continuously releasing deslorelin for a long time.

Abstract: A solvent-removing apparatus according to an embodiment includes a tank body accommodating an emulsion including first source material in a continuous phase and second source material in a dispersed phase, a fluid supply unit for supplying fluid into the tank body to cause the emulsion to circulate, and a discharge unit for discharging the gas in the tank body to the outside.

Abstract: The present invention relates to microparticles comprising moxidectin and a biodegradable polymer, wherein the microparticles comprising moxidectin have a shape allowing a moxidectin drug to be uniformly distributed in spherical biodegradable polymer particles, and the average particle diameter of the microparticles is 45-130 ?m, depending on the type of polymer. The present invention relates to: extended release microparticles capable of continuously maintaining a heartworm disease prevention effect for 3 months to 6 months by administering microparticles comprising moxidectin; and a preparation method therefor. In addition, the present invention is prepared such that the average diameters of the particles have a predetermined micrometer size, and thus reduces a foreign body sensation and pain during administration into an animal through injection, thereby enabling administration through injection to be facilitated.

Abstract: In the present invention, two adjacent supply lines for supplying two immiscible fluids are spirally disposed on a substrate where microchannels for microsphere production based on a droplet-based highly controlled method for mass-production of microspheres (HCMMM) are formed, and microsphere forming parts each comprising microchannels are arranged between and along the two supply lines, whereby a much larger amount of microspheres can be produced. Further, the two supply lines are disposed in a spiral configuration, and the microsphere forming parts can be disposed by branching microchannels from the two supply lines on inner and outer sides of the spiral configuration, whereby the limited space on a wafer normally having a circular shape can be maximally used to form multiple microsphere forming parts.

Abstract: The present invention provides microparticles containing leuprolide and a method for producing the same. When the microparticles are administered by injection, they may lower pain due to their small size, control the release rate of leuprolide at a target site, prevent excessive release of leuprolide at an initial stage, enable exposure to a sufficient amount of the drug to exhibit the effect of leuprolide, and exhibit the effect of leuprolide for 1 month or more. The present invention also provides a method for producing microparticles, in which the microparticles have a uniform particle size and a smooth surface and may exhibit the effect of releasing leuprolide sustainably over a long period of time.

Abstract: A sustained-release injectable composition containing naltrexone, and a method for producing the same are described. The composition may prevent the initial burst release of naltrexone by controlling the release rate of naltrexone at a target site, and maintain a plasma naltrexone concentration sufficient to exhibit the effect of naltrexone by releasing naltrexone continuously for one month. In addition, the production method is capable of producing microparticles that are homogeneous and of good quality while having high encapsulation efficiency for naltrexone, a poorly soluble drug.

Abstract: A method for producing microparticles containing a poorly soluble drug, and microparticles produced by the method are proposed. According to the method for preparing microparticles, it is possible to produce microparticles that are uniform and of good quality and have high encapsulation efficiency for the poorly soluble drug and low contents of residual organic solvents, by using at least two organic solvents.

Abstract: The present disclosure relates to a method for manufacturing lipid nanoparticles and an apparatus for manufacturing the same, which are capable of increasing a production yield in a subsequent eradication filtration process and the like by not requiring a separate process for sorting the manufactured lipid nanoparticles. In addition, by deviating from an existing optimal drug and lipid ratio, a content of ionizable lipid that causes a problem of toxicity when injected into the body may be lowered, and uniform-sized lipid nanoparticles may be manufactured.

Abstract: A solvent removing apparatus includes a container containing an emulsion comprising a first raw material of a continuous phase and a second raw material of a dispersed phase, an impeller rotating in the container to stir the emulsion, and a foam breaker spaced apart from the impeller on an upper portion of the impeller, positioned below a surface of the emulsion to be submerged in the emulsion when the emulsion is calm, and rotating to reduce foam generated during stirring of the emulsion.

Abstract: The present invention relates to microparticles comprising moxidectin and a biodegradable polymer, wherein the microparticles comprising moxidectin have a shape allowing a moxidectin drug to be uniformly distributed in spherical biodegradable polymer particles, and the average particle diameter of the microparticles is 80-130 ?m. The present invention relates to: extended release microparticles capable of continuously maintaining a heartworm disease prevention effect for 3 months to 6 months by administering microparticles comprising moxidectin; and a preparation method therefor. In addition, the present invention is prepared such that the average diameters of the particles have a predetermined micrometer size, and thus reduces a foreign body sensation and pain during administration into an animal through injection, thereby enabling administration through injection to be facilitated.